Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas

This publication has 125 references indexed in Scilit:

• Interplay of m⁶A and histone modifications contributes to temozolomide resistance in glioblastoma
  Clinical and Translational Medicine, 2021
• Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells
  Stem Cells, 2018
• Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA‐101 in glioblastoma
  Cancer Medicine, 2018
• Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B
  Molecular Oncology, 2018
• Concepts and Molecular Aspects in the Polypharmacology of PARP‐1 Inhibitors
  ChemMedChem, 2015
• Long‐term outcome of 4,040 children diagnosed with pediatric low‐grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database
  Pediatric Blood & Cancer, 2014
• Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program
  Pediatric Blood & Cancer, 2013
• Overexpression of the long non‐coding RNA MEG3 impairs in vitro glioma cell proliferation
  Journal of Cellular Biochemistry, 2012
• The DNA demethylating agent 5‐aza‐2′‐deoxycytidine activates NY‐ESO‐1 antigenicity in orthotopic human glioma
  International Journal of Cancer, 2008
• Regularly methylated novel pro‐apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder
  International Journal of Cancer, 2006